BMRN

BioMarin Pharmaceutical Inc. [BMRN] Stock Forecast

Q: What is BioMarin Pharmaceutical Inc. stock symbol ?

BioMarin Pharmaceutical Inc. is a US stock, located in San rafael of Ca and trading under the symbol BMRN

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

BMRN Stock Summary

Earnings have grown 15.42% per last year.

EPS has been increasing for the past 3 years (Yearly statements)

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 quarters (Quarter statements)

BMRN has less than 1 year of cash runway

Top 10 Correlated ETFs

BMRN

Top 10 Correlated Stocks

BMRN

In the News

BMRN Financial details

Company Rating

Buy

Market Cap

17.5B

Income

167.65M

Revenue

2.42B

Book val./share

26.27

Cash/share

4008.12

Dividend

Dividend %

Employees

3.4K

Optionable

Shortable

Yes

Earnings

24 Apr 2024

P/E

97.76

Forward P/E

PEG

57.15

P/S

6.78

P/B

3.31

P/C

0.02

P/FCF

317.64

Quick Ratio

6423.65

Current Ratio

25.11

Debt / Equity

0.22

LT Debt / Equity

0.12

EPS (TTM)

0.89

EPS next Y

EPS next Q

EPS this Y

17.11%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

7.26%

Revenue Q/Q

10.28%

EPS Q/Q

-47.62%

SMA20

7.06%

SMA50

2.25%

SMA100

4.6%

Inst Own

81.35%

Inst Trans

0.87%

ROA

ROE

ROC

0.02%

Gross Margin

77%

Oper. Margin

Profit Margin

Payout

43%

Shs Outstand

Shs Float

Target Price

52W Range

76.02-100.38

52W High

-9.74%

52W Low

+18.76%

RSI

Rel Volume

0.46

Avg Volume

1.36M

Volume

630.56K

Perf Week

0.06%

Perf Month

5.09%

Perf Quarter

10.11%

Perf Half Y

6.45%

Beta

0.32

Volatility

0.66%, 2.5%

Prev Close

-0.23%

Price

90.26

Change

-0.97%

BMRN Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	9.52	10.29	10.1	11.31	12.88
Net income per share	-0.13	4.72	-0.35	0.76	0.89
Operating cash flow per share	0.27	0.47	1.67	0.95	0.85
Free cash flow per share	-0.64	-0.29	1.01	0.24	0.27
Cash per share	4.21	5.89	5.54	6.97	5.72
Book value per share	17.44	22.71	23.36	24.85	26.36
Tangible book value per share	13.79	19.32	20.16	21.96	23.75
Share holders equity per share	17.44	22.71	23.36	24.85	26.36
Interest debt per share	4.87	6.17	6.04	5.99	5.93
Market cap	15.14B	15.85B	16.15B	19.17B	18.11B
Enterprise value	15.55B	16.28B	16.65B	19.53B	18.49B
P/E ratio	-634.76	18.56	-252.11	135.44	108.03
Price to sales ratio	8.88	8.52	8.75	9.15	7.49
POCF ratio	313.66	185.73	53.05	109	113.72
PFCF ratio	-131.47	-304	87.18	432.2	350.66
P/B Ratio	4.85	3.86	3.78	4.17	3.66
PTB ratio	4.85	3.86	3.78	4.17	3.66
EV to sales	9.12	8.75	9.02	9.32	7.64
Enterprise value over EBITDA	-699.03	-2.78K	346.62	122.44	70.58
EV to operating cash flow	322.17	190.72	54.66	111.04	116.1
EV to free cash flow	-135.03	-312.17	89.83	440.28	357.99
Earnings yield	0	0.05	0	0.01	0.01
Free cash flow yield	-0.01	0	0.01	0	0
Debt to equity	0.27	0.26	0.26	0.24	0.22
Debt to assets	0.18	0.19	0.18	0.17	0.16
Net debt to EBITDA	-18.46	-72.82	10.24	2.25	1.45
Current ratio	2.08	4.76	4.21	4.67	2.51
Interest coverage	-5.35	-3.28	-3.91	3.6	9.09
Income quality	-2.02	0.1	-4.75	1.24	0.95
Dividend Yield	0	0	0	0	0
Payout ratio	-0.46	0.08	-0.05	0.11	0
Sales general and administrative to revenue	0	0.18	0.19	0.19	0.19
Research and developement to revenue	0.42	0.34	0.34	0.31	0.31
Intangibles to total assets	0.14	0.1	0.1	0.08	0.07
Capex to operating cash flow	-3.39	-1.61	-0.39	-0.75	-0.68
Capex to revenue	-0.1	-0.07	-0.06	-0.06	-0.04
Capex to depreciation	-1.55	-1.31	-1.1	-1.29	-1.03
Stock based compensation to revenue	0.09	0.1	0.11	0.09	85.61
Graham number	7.23	49.13	13.57	20.67	23.01
ROIC	-0.01	0.38	-0.01	0.01	0.02
Return on tangible assets	-0.01	0.16	-0.01	0.02	0.03
Graham Net	-1.06	0.05	-0.28	1.69	1.13
Working capital	1.01B	1.85B	1.73B	2.16B	1.78B
Tangible asset value	2.47B	3.49B	3.69B	4.07B	4.46B
Net current asset value	374.49M	600.2M	541.8M	979.54M	1.07B
Invested capital	0.27	0.26	0.26	0.24	0.22
Average receivables	360.02M	412.88M	410.88M	417.36M	547.51M
Average payables	503.96M	381.03M	192.22M	212.12M	273.37M
Average inventory	605.57M	689.41M	737.61M	835.38M	1B
Days sales outstanding	80.84	87.96	73.82	80.33	95.61
Days payables outstanding	579.41	133.27	149.72	174.5	199.56
Days of inventory on hand	690.75	486.33	602.5	674.72	700.31
Receivables turnover	4.52	4.15	4.94	4.54	3.82
Payables turnover	0.63	2.74	2.44	2.09	1.83
Inventory turnover	0.53	0.75	0.61	0.54	0.52
ROE	-0.01	0.21	-0.02	0.03	0.03
Capex per share	-0.91	-0.76	-0.65	-0.71	-0.57

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	2.89	3.18	3.16	3.11	3.43
Net income per share	0	0.27	0.3	0.21	0.11
Operating cash flow per share	0.04	-0.4	0.37	0.72	0.15
Free cash flow per share	-0.16	-0.53	0.25	0.6	-0.05
Cash per share	6.94	6.17	6.23	5.98	4.01K
Book value per share	24.74	24.96	25.45	26.02	26.27
Tangible book value per share	21.87	22.16	22.75	23.37	23.67
Share holders equity per share	24.74	24.96	25.45	26.02	26.27
Interest debt per share	5.9	5.88	5.84	5.79	5.8
Market cap	19.25B	18.15B	16.29B	16.65B	18.17B
Enterprise value	19.61B	18.66B	16.68B	16.95B	-735.87B
P/E ratio	-19.33K	89.24	72.68	103.11	222.98
Price to sales ratio	35.82	30.61	27.4	28.42	28.12
POCF ratio	2.84K	-245.52	232.53	122.77	661.25
PFCF ratio	-651	-183.91	344.19	148.39	-1.97K
P/B Ratio	4.18	3.9	3.41	3.4	3.67
PTB ratio	4.18	3.9	3.41	3.4	3.67
EV to sales	36.48	31.46	28.06	28.93	-1.14K
Enterprise value over EBITDA	1.85K	214.71	202.97	349.46	-17.91K
EV to operating cash flow	2.89K	-252.33	238.1	124.99	-26.78K
EV to free cash flow	-663.12	-189.02	352.45	151.07	79.87K
Earnings yield	0	0	0	0	0
Free cash flow yield	0	-0.01	0	0.01	0
Debt to equity	0.24	0.23	0.23	0.22	0.22
Debt to assets	0.17	0.17	0.17	0.16	0.16
Net debt to EBITDA	33.75	5.8	4.75	6.2	-18.36K
Current ratio	4.67	4.75	4.94	2.54	25.11
Interest coverage	-3.84	16.33	15.12	6.04	2.33
Income quality	-27.25	-1.45	1.25	3.36	1.35
Dividend Yield	0	0	0	0	0
Payout ratio	-87.87	1.01	0.29	0.11	0
Sales general and administrative to revenue	0.23	0.18	0.17	0.17	0.22
Research and developement to revenue	0.32	0.29	0.3	0.33	0.32
Intangibles to total assets	0.08	0.08	0.08	0.07	0.07
Capex to operating cash flow	-5.36	0.33	-0.32	-0.17	-1.34
Capex to revenue	-0.07	-0.04	-0.04	-0.04	-0.06
Capex to depreciation	-1.48	-0.94	-0.89	-0.91	-1.37
Stock based compensation to revenue	0.09	0.09	0.08	0.08	0.08
Graham number	0.86	12.37	13.07	11.21	7.99
ROIC	0	0.01	0.01	0	0
Return on tangible assets	0	0.01	0.01	0.01	0
Graham Net	1.68	1.53	1.79	1.12	4K
Working capital	2.16B	2.24B	2.35B	1.79B	2.84B
Tangible asset value	4.07B	4.14B	4.28B	4.4B	4.46B
Net current asset value	979.54M	1.07B	1.17B	1.09B	1.07B
Invested capital	0.24	0.23	0.23	0.22	0.22
Average receivables	440.47M	529.61M	604.07M	591.36M	603.1M
Average payables	219.2M	248.01M	271.36M	289.66M	492.26M
Average inventory	866.77M	906.5M	947.23M	1B	1.07B
Days sales outstanding	77.24	90.75	92.36	87.93	88.26
Days payables outstanding	163.5	167.52	174.1	193.15	453.82
Days of inventory on hand	632.16	581.4	611.07	661.52	735.52
Receivables turnover	1.17	0.99	0.97	1.02	1.02
Payables turnover	0.55	0.54	0.52	0.47	0.2
Inventory turnover	0.14	0.15	0.15	0.14	0.12
ROE	0	0.01	0.01	0.01	0
Capex per share	-0.2	-0.13	-0.12	-0.12	-0.19

BMRN Frequently Asked Questions

What is BioMarin Pharmaceutical Inc. stock symbol ?

BioMarin Pharmaceutical Inc. is a US stock , located in San rafael of Ca and trading under the symbol BMRN

What is BioMarin Pharmaceutical Inc. stock quote today ?

BioMarin Pharmaceutical Inc. stock price is $90.26 today.

Is BioMarin Pharmaceutical Inc. stock public?

Yes, BioMarin Pharmaceutical Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 1.36M
Market Capitalization 17.5B
Employee 3.4K
CEO Mr. Alexander Hardy
Headquarters San Rafael,CA,US
IPO Date 1999-07-26
Website https://www.biomarin.com

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.